ライフサイエンスコーパス: dysphoric

1 diction and chronic pain, but are limited by dysphoric and aversive side effects.

2 e increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/ne

3 One was characterized by symptoms of dysphoric arousal (anhedonia, anxiety, hypervigilance) w

4 ences with others, for example by undergoing dysphoric collective rituals together, can lead to "iden

5 ppa opioid receptor (KOR) system encodes the dysphoric component of the stress response and controls

6 Premenstrual dysphoric disorder (PMDD) affects over 5% of women, with

7 allopregnanolone in women with premenstrual dysphoric disorder (PMDD) and in asymptomatic control wo

8 in healthy women and those with premenstrual dysphoric disorder (PMDD) and that a menstrual cycle pha

9 te evidence for the validity of premenstrual dysphoric disorder (PMDD) and the inclusion of the disor

10 Premenstrual dysphoric disorder (PMDD) disrupts the lives of millions

11 tedly experienced by women with Premenstrual Dysphoric Disorder (PMDD) during the late luteal phase o

12 is substantial information that premenstrual dysphoric disorder (PMDD) is a clinically significant di

13 Premenstrual dysphoric disorder (PMDD) is a common mood disorder, cha

14 Premenstrual dysphoric disorder (PMDD) is characterized by affective,

15 Premenstrual Dysphoric Disorder (PMDD) is characterized by debilitati

16 tric illnesses tested, although premenstrual dysphoric disorder (PMDD) may be an exception.

17 y demonstrated that symptoms of premenstrual dysphoric disorder (PMDD) remit during ovarian hormone s

18 Premenstrual dysphoric disorder (PMDD) symptoms are eliminated by ova

19 are efficacious treatments for premenstrual dysphoric disorder (PMDD) when given daily or for half o

20 mood and behavioral symptoms in premenstrual dysphoric disorder (PMDD), a common, recently recognized

21 premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD), are associated with significa

22 e distinguishable in women with premenstrual dysphoric disorder (PMDD).

23 se women also meet criteria for premenstrual dysphoric disorder (PMDD).

24 epilepsy and enhance anxiety in premenstrual dysphoric disorder (PMDD).

25 sychiatric disorders, including premenstrual dysphoric disorder (PMDD).

26 errecognized conditions such as Premenstrual Dysphoric Disorder (PMDD).

27 Patients with premenstrual dysphoric disorder (whose symptoms had remitted during t

28 led protocol to nine women with premenstrual dysphoric disorder and 11 healthy female volunteers in t

29 were measured in 27 women with premenstrual dysphoric disorder and 21 comparison women during the th

30 Women with premenstrual dysphoric disorder and a past history of major depressiv

31 ere particularly pronounced for premenstrual dysphoric disorder and for PMDs with symptom onset befor

32 h major depression, and 10 with premenstrual dysphoric disorder and in 34 normal comparison subjects.

33 ts to examine the literature on premenstrual dysphoric disorder and provide recommendations regarding

34 icipation, 243 met criteria for premenstrual dysphoric disorder and were randomized; 200 women comple

35 h, including menstruation (with premenstrual dysphoric disorder appearing for the first time in recen

36 Premenstrual dysphoric disorder appears to be associated with seroton

37 anic disorder and patients with premenstrual dysphoric disorder are highly susceptible to CO(2)-induc

38 In women with premenstrual dysphoric disorder but no past major depressive disorder

39 s of serotonergic deficiency in premenstrual dysphoric disorder by measuring the prolactin response t

40 The patients with premenstrual dysphoric disorder experienced a return of symptoms 24 h

41 normal subjects, the women with premenstrual dysphoric disorder had a significantly blunted prolactin

42 icacy for premenstrual syndrome/premenstrual dysphoric disorder is a general or more serotonergic eff

43 Premenstrual dysphoric disorder is an important cause of symptoms and

44 Premenstrual dysphoric disorder is often associated with major depres

45 d a state-dependent decrease in premenstrual dysphoric disorder might imply a possible continuum betw

46 he panic rate for patients with premenstrual dysphoric disorder was similar to that for panic disorde

47 to determine whether women with premenstrual dysphoric disorder with or without prior major depressiv

48 anxiety, postpartum depression, premenstrual dysphoric disorder, and schizophrenia and (2) whether an

49 posttraumatic stress disorder, premenstrual dysphoric disorder, and social phobia.

50 uding premenstrual syndrome and premenstrual dysphoric disorder, have symptom onset during the teen y

51 or depression and patients with premenstrual dysphoric disorder, respectively).

52 he menstrual cycle, as in DSM-5 premenstrual dysphoric disorder, symptom changes of similar magnitude

53 Premenstrual dysphoric disorder, which affects 2%-5% of premenopausal

54 ch as postpartum depression and premenstrual dysphoric disorder.

55 efficacy of SSRI treatment for premenstrual dysphoric disorder.

56 nhibitors (SSRIs) in women with premenstrual dysphoric disorder.

57 evere premenstrual syndrome and premenstrual dysphoric disorder.

58 involved in the pathogenesis of premenstrual dysphoric disorder.

59 uch as acne, endometriosis, and premenstrual dysphoric disorder.

60 th the observation of an association between dysphoric disorders of epilepsy and POE described nearly

61 ween subtypes of depressive and premenstrual dysphoric disorders.

62 nd to be an important site of action for the dysphoric effects of dynorphin-kappa-opioid receptor sys

63 signaling results in analgesia, whereas the dysphoric effects of KOR agonists are mediated by a diff

64 this endogenous opioid peptide mediates the dysphoric effects of marijuana.

65 eptor (KOR) system in the brain mediates the dysphoric effects of stress, and KOR antagonists may hav

66 y been revived by studies showing that their dysphoric effects require arrestin recruitment, whereas

67 one+dronabinol 10 mg produced a high rate of dysphoric effects, and hydromorphone+dronabinol 5 mg and

68 ignaling may be effective analgesics lacking dysphoric effects.

69 ns analysis of participants who had a single dysphoric episode, and they were replicated in an indepe

70 ted that no adverse life events caused their dysphoric episodes reported fatigue, appetite gain, and

71 Practically, our account of how shared dysphoric experiences produce identity fusion helps us b

72 Dysphoric features are statistically salient in patients

73 pain thresholds, anxiety-like behavior, and dysphoric-like responses.

74 e that varenicline and cytisine diminish the dysphoric-like state associated with nicotine withdrawal

75 In this view, dysphoric mania is associated with paranoid-destructive

76 Effective treatment of acute or dysphoric mania is provided by modern antipsychotics, so

77 s and may be a clinical marker for recurrent dysphoric mania.

78 tidepressants during bipolar mixed states or dysphoric manias.

79 pressive mixed states (mixed depression) and dysphoric (mixed) hypomania (opposite polarity symptoms

80 Depressive or dysphoric-mixed episodes were more prevalent in pregnant

81 ater total depressive symptoms, specifically dysphoric mood and somatic complaints.

82 st that persistent mood symptoms and overall dysphoric mood are associated with the early perimenopau

83 crease a woman's vulnerability to an overall dysphoric mood during the early perimenopausal period.

84 the changing hormonal milieu contributes to dysphoric mood during transition to menopause.

85 17.0% of the association between stress and dysphoric mood for 27 months after imaging (beta = .04,

86 ponse in terms of perceptual alterations and dysphoric mood relative to those without such a family h

87 ore symptoms of hypothyroidism (P<0.001) and dysphoric mood states (P<0.001) after withdrawal of thyr

88 anning is associated with fewer symptoms and dysphoric mood states.

89 ect of being early perimenopausal on overall dysphoric mood was greatest among women with an educatio

90 Depressive symptoms, particularly dysphoric mood, presage future cognitive losses among el

91 Five independent factors representing dysphoric mood, psychomotor pressure, psychosis, increas

92 features of mania and 5 features related to dysphoric mood.

93 such as early alcohol or nicotine use, early dysphoric or anhedonic mood, conduct disorder, and child

94 ssified as classic (predominately euphoric), dysphoric, or depressed.

95 y is often beneficial for gender-diverse or -dysphoric patients.

96 y of patients best characterized as having a dysphoric personality constellation.

97 Kappa-opioid receptor (KOR) agonists have dysphoric properties in humans and are aversive in roden

98 Here, we report that the dysphoric properties of chronic stress are encoded by th

99 ime elapses after trauma, fear circuitry and dysphoric PTSD symptoms appear to emerge as connected ne

100 Elevations in ICSS thresholds reflect a dysphoric state and a lowering of thresholds is indicati

101 melancholia report a distinct and intrusive dysphoric state during internally generated thought.

102 opioid system contributes to depressive and dysphoric states, but whether this system contributes to

103 isorder, especially for early depressive and dysphoric states.

104 iated transcription within the NAc regulates dysphoric states.

105 ink between cocaine-cue responses and normal dysphoric states.

106 s on medication also had fewer fixations for dysphoric stimuli compared with depressed participants n

107 healthy volunteers and resolution of chronic dysphoric symptoms in depressed patients were examined w

108 different mechanisms underlie cognitive and dysphoric symptoms in nondemented patients with Parkinso

109 prove quality of life, and further alleviate dysphoric symptoms in transgender women.

110 Dysphoric symptoms, such as sadness and anhedonia, respo

111 sed transdiagnostic treatments for loss (ie, dysphoric) symptoms.

112 d with scores on mnemonic, visuospatial, and dysphoric tests.

113 assessing selective attention for positive, dysphoric, threatening, and neutral stimuli in addition